FIND CLINICAL TRIALS

 

AXL & MER RECEPTOR TYROSINE KINASES

 
 
 

Incyte is developing a small molecule inhibitor of AXL and MER.

AXL and MER belong to the TAM family of receptor tyrosine kinases (RTKs), broadly expressed in a variety of tissues. AXL and MER are overexpressed, amplified, and/or translocated in many solid tumors and hematological malignancies.

The aberrant activation of these RTKs plays important roles in tumor growth, survival, angiogenesis, metastasis, and chemoresistance.

In addition, the tumor microenvironment can subvert the functions of AXL and MER to evade immune responses through a number of mechanisms, such as by enhancing clearance of apoptotic material, shifting tumor-associated macrophage differentiation toward an immunosuppressive phenotype, curtailing antigen-presenting cell activity, and disabling the anti-metastatic functions of natural killer cells.

The therapeutic inhibition of AXL and MER signaling may have direct anti-tumor effects while also promoting host immune responses against tumors.

MOLECULE LIBRARY

image show jak target.image of pi3kδ target.image of fgfr target.image of brd target.image of pim target molecule.image of lsd1 target molecule.image shows ido1 target.image shows arg target.image of pd-1 target molecule. image of gitr target molecule. image of ox40 target molecule.  image of Tim-3 target moleculeimage of Lag-3 target moleculeimage of Axr target molecule